Can AI make life-or-death clotting results arrive sooner?
A peer-reviewed review found 27 studies applying AI to viscoelastic haemostatic assays. Some models may infer useful results within minutes, but small cohorts, internal validation and scarce calibration data mean faster predictions are not yet proven to improve patient outcomes.
The short version
- What happened
- The authors searched five databases, screened 493 unique records and included 27 studies spanning trauma, surgery and transplantation, cardiology, obstetrics, critical care and haemostatic diagnosis.
- Who it affects
- A reliable early prediction could reduce uncertainty during major bleeding and help clinicians prepare treatment sooner, but that benefit has not yet been demonstrated in patient outcomes.
- What remains unproven
- This is a scoping review of 27 heterogeneous studies, not a meta-analysis of one comparable outcome and not a trial of AI-guided transfusion.
Keep in mind
This is a scoping review of 27 heterogeneous studies, not a meta-analysis of one comparable outcome and not a trial of AI-guided transfusion.
Many included studies used small cohorts, internal validation or mixed clinical inputs; calibration and independent external testing were uncommon.
The accepted article is peer reviewed and citable, but the journal says the text may still change during copy-editing and typesetting before the final version of record.
Source analysis · 1 linked source. Primary analysed source date: 30 September 2026.
Read the full report · 6 min The evidence, methods, implications and limitations
The review maps a small and uneven evidence base
When a patient is bleeding heavily, clinicians need to know quickly whether blood is forming and maintaining a clot. Viscoelastic haemostatic assays, commonly delivered through systems such as thromboelastography or rotational thromboelastometry, track the physical development of a clot over time. They can help teams decide whether a patient may need plasma, platelets, fibrinogen or another intervention. A peer-reviewed scoping review published on 30 September asks whether artificial intelligence can extract useful answers earlier from those tests.
The review was prospectively registered and followed PRISMA-ScR and Joanna Briggs Institute guidance. Its authors searched five databases, screened 493 unique records and retained 27 studies. Those studies covered trauma, perioperative and transplant care, vascular and cardiac settings, obstetrics, intensive care and haemostatic diagnosis. The denominator is therefore 27 included studies, not 27 clinical trials and not one combined patient population. The authors map the field rather than calculate a pooled treatment effect.[1]
Minutes may matter, but a faster proxy is not a patient outcome
The most plausible near-term use is to infer a later clotting measurement from an earlier part of the test. Several studies used early amplitudes measured at five or ten minutes—often called A5 and A10—to predict later values or classify coagulopathy. The review concludes that minute-level acceleration is supported strongly enough to justify careful prospective testing. It proposes three-to-five-minute prediction from raw signals as a realistic research target, while treating sub-minute and 20-second prediction as hypotheses rather than established capabilities.
That distinction is important. Predicting a later laboratory value sooner is not the same as showing that a patient receives the right treatment faster, avoids unnecessary blood products or survives. A model can reproduce the analyser's eventual output yet still fail in a different hospital, device version or clinical population. A rushed implementation could also make an incorrect early estimate appear more authoritative than an incomplete conventional trace. The paper does not establish an autonomous treatment pathway, and clinicians should not read its findings as permission to bypass local validation or expert review.[1]
Most models did not begin with the raw test signal
Most included studies treated measurements already generated by the viscoelastic assay as model inputs alongside clinical or laboratory variables. Three studies instead used the assay to define an outcome or phenotype, and only one modelled raw device signals directly. That matters because the boldest promise—reading the evolving trace before the instrument has completed its usual calculation—depends on raw, time-resolved data. Results from models built on later derived values cannot automatically validate that use.
The studies also differed in patient group, device, outcome and modelling approach. Some reported high discrimination, but the review identifies recurring weaknesses: small cohorts, mixed-variable models that make the contribution of the clotting test hard to isolate, internal rather than external validation, conference abstracts with limited methodological detail, sparse calibration reporting and little testing across institutions. Discrimination asks whether higher-risk cases tend to receive higher scores. Calibration asks whether the predicted probabilities match what actually happens; without it, an apparently accurate model may still mislead treatment decisions.[1]
Practical benefit depends on workflow, devices and local populations
For patients, an effective early-warning model could shorten uncertainty during major bleeding and help teams prepare the right products sooner. It might also reduce avoidable transfusion if it can reliably show that a product is not needed. Those benefits remain potential, not demonstrated outcomes of this review. They must be weighed against false reassurance, unnecessary treatment and automation bias when a prediction conflicts with the evolving trace or the patient's condition.
The authors are based at Beijing Tongren Hospital and Beijing Anzhen Hospital in China, while the evidence they reviewed spans several clinical settings and research groups. Global use will still require local testing because transfusion protocols, patient mix, staffing and analyser platforms vary across hospitals and countries. Access is another issue: institutions able to capture raw device data and maintain clinical models may advance faster than under-resourced emergency and surgical services, even where the burden of bleeding is high.[1]
What would change our assessment
Confidence would rise with prospective, multi-centre studies that lock the model before testing, publish calibration as well as discrimination, compare performance across devices and patient groups, and measure treatment time, blood-product use, complications and survival. The strongest evidence would come from workflow studies showing that clinicians can act on an early output safely, with clear rules for uncertainty and disagreement between the model and the conventional test.
The assessment would weaken if later studies reproduce only retrospective accuracy, omit failed sites or depend on variables unavailable at the moment of prediction. This review is valuable because it narrows the credible claim: AI may help extract useful information from clotting tests several minutes earlier. It does not yet show that those minutes translate into better care.[1]